The global cancer biomarkers market size reached US$ 21.7 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 47.66 Billion by 2027 exhibiting a growth rate (CAGR) of 13.20% during 2022-2027.
Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Cancer biomarkers refer to biological molecules that indicate the presence of cancerous cells in the tissues, blood, or other fluids of the body. They are produced either by other tissues in the body or the cancer cell itself in response to cancer. Some commonly diagnosed types of cancer include cervical, lung, prostate, breast, lung, and colorectal cancer.
They are extensively used as surrogate endpoints, prognostics, diagnostics, and personalized medicines. Some commonly available biomarkers include proteins, enzymes, genes, nucleic acids, specific cells, and peptides. In recent years, cancer biomarkers have gained traction as it is used for diagnosing the disease, monitoring their progression, distinguishing between invasive and non-invasive tumors, predicting the chances of recurrences, and recording therapeutic treatment efficacy.
Cancer Biomarkers Market Trends and Drivers:
One of the primary factors driving the market is the increasing number of individuals diagnosed with cancer worldwide. Additionally, the increasing incidences of lung cancer due to the rising smoking trends, upsurge in pollution, and poor ingestion habits are propelling the market growth.
Furthermore, there has been a significant rise in health awareness amongst patients and healthcare professionals about the importance of early diagnoses. Besides this, various technological advancements in genetic biomarker discovery, including polymerase chain reaction (PCR), next-generation sequencing (NGS), gene expression profiling (microarray), and artificial intelligence (AI) that help in predicting the recurrence of cancer after treatment, are catalyzing the market growth.
Other growth-inducing factors include extensive research and development (R&D) activities, growth in the healthcare industry, and the implementation of various government initiatives for improving drug development procedures.
Request a PDF Sample Copy for more detailed market insights: https://www.imarcgroup.com/cancer-biomarkers-market/requestsample
Report Segmentation:
The report has been segmented the market into following categories:
Breakup by Profiling Technology:
- Omic Technologies
- Imaging Technologies
- Immunoassays
- Cytogenetics
Breakup by Biomolecule:
- Genetic Biomarkers
- Protein Biomarkers
- Glyco-Biomarkers
Breakup by Cancer Type:
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Others
Breakup by Application:
- Diagnostics
- Prognostics
- Risk Assessment
- Drug Discovery and Development
- Others
Breakup by End User:
- Hospitals
- Academic and Research Institutions
- Ambulatory Surgical Centers
- Diagnostic Laboratories
- Others
Ask Analyst for customized Report with TOC & List of Figure: https://www.imarcgroup.com/cancer-biomarkers-market
By Geography:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
List of Major Key Players:
The major players in the market Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson and Company, bioMérieux SA, Danaher Corporation, F. Hoffmann-La Roche AG, General Electric Company, Illumina Inc., Qiagen N.V., Sino Biological Inc. and Thermo Fisher Scientific Inc.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800